Join our daily newsletter At The Bell to receive exclusive market insights
- ResApp Health (RAP) has secured a one-year, non-exclusive licencing agreement with AstraZeneca’s Japanese subsidiary
- Under the agreement, ResApp will licence its cough counting technology to the COVID-19 vaccine producer for use in its smartphone app
- The information gathered from this can then provide insight into the progression and management of respiratory disease
- It’s the first time this particular technology will be used outside of a clinical trial environment after previously been used by AstraZeneca in a lung cancer trial
- ResApp is up a solid 17.2 per cent on the market, trading at 6.8 cents per share
ResApp Health (RAP) has secured a one-year, non-exclusive licencing agreement with AstraZeneca’s Japanese subsidiary.
It marks ResApp’s second licencing arrangement with the pharmaceutical, which more recently garnered global attention for its COVID-19 vaccine production.
Under the arrangement, ResApp is set to licence its cough counting technology for
use in a program to support asthma patients. This will also be the first time the technology has been used outside of clinical trials.
It marks the company’s second licensing agreement with the AstraZeneca, which was secured in October last year which used the technology in a lung cancer clinical trial.
ResApp’s technology measures the frequency of patient coughs over extended periods of time, which then helps provide an insight into the progression and management of the respiratory disease.
More specifically, the cough counting tech will be included in AstraZeneca’s smartphone app, allowing patients to monitor their symptoms at home.
Broadly, ResApp describes the agreement as a significant validation from a leading global pharmaceutical.
The companies are set to work together to integrate the product into the smartphone app ensuring it meets the group’s specifications for use in the Japanese market.
AstraZeneca will pay an undisclosed annual licence fee to ResApp for each patient provided with AstraZeneca’s asthma management smartphone app.
ResApp is up a solid 17.2 per cent on the market, trading at 6.8 cents per share at 11:10 am AEDT.
